盐酸缬更昔洛韦片治疗效果怎么样？

The tablet is the L-valyl ester (prodrug) of ganciclovir, which is rapidly converted into ganciclovir by esterases in the small intestine and liver after oral administration. Valganciclovir hydrochloride tablets are a synthetic 2’-deoxyguanylate analogue that inhibits herpes virus replication in vitro and in vivo. Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

Valganciclovir Hydrochloride Tablets In cells infected by cytomegalovirus (CMV), valganciclovir hydrochloride tablets are first phosphorylated by the viral protein kinase UL97 into ganciclovir monophosphate, and then further phosphorylated by intracellular protein kinases into ganciclovir triphosphate, and then slowly metabolized within the cell. After removal of extracellular ganciclovir with Valganciclovir Hydrochloride Tablets, the half-life of ganciclovir in HSV- or HCMV-infected cells was observed to be 18 hours and 6 to 24 hours, respectively. Since the phosphorylation process relies heavily on viral protein kinases, phosphorylation of valganciclovir hydrochloride tablets occurs preferentially in cells infected by the virus.

Valganciclovir hydrochloride tablets are suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

What is the therapeutic effect of Valganciclovir Hydrochloride Tablets?

The safety and efficacy of valganciclovir hydrochloride tablets treatment were verified in two different trials: The antiviral effect of valganciclovir hydrochloride tablets was clinically confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with valganciclovir hydrochloride tablets, and the U.S. Food and Drug Administration (FDA) approved the increased use of valganciclovir hydrochloride tablets in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with valganciclovir hydrochloride tablets reduced the incidence of CMV disease in high-risk adult renal transplant patients from 36.8% (for patients who received 100 days of treatment) to 16.8% (for patients who received 200 days of treatment at one year after receiving a kidney transplant) (p < 0.0001). 1.2 The overall safety profile of the tablets did not change when prophylaxis was extended in high-risk renal transplant patients.